Ildong Pharmaceutical Co., Ltd. (249420) Decline -0.88% on Jun 15

June 15, 2018 - By Vivian Park

Shares of Ildong Pharmaceutical Co., Ltd. (KRX:249420) last traded at 22600, representing a move of -0.88%, or -200 per share, on volume of 11,948 shares. After opening the trading day at 22850, shares of Ildong Pharmaceutical Co., Ltd. traded in a close range. Ildong Pharmaceutical Co., Ltd. currently has a total float of 21.59 million shares and on average sees 124,059 shares exchange hands each day. The stock now has a 52-week low of 16090.9 and high of 29600.

How KOSPI Transforms South Korea Into A Global Leader

One of the leading economies backing the immense growth of the Asian economy is that of South Korea. The country has long been proven itself as a valuable asset in driving growth and maximizing potentials in the long run. It is not easy for companies to get there, but as Ildong Pharmaceutical Co., Ltd. shows it is possible. Its rich and healthy equity market is only one of the many proofs of South Korea’s capabilities.

About the KOSPI

The Korea Composite Stock Price Index (KOSPI) is the benchmark, market-capitalization-weighted index in South Korea. Ildong Pharmaceutical Co., Ltd. is inside KOSPI register. First published in 1983, it has replaced the Korea Composite Stock Price Index (KCSPI), which was like the Dow Jones Industrial Average (DJIA) of the US equity market.

The KOSPI has a base value of 100 points— the base date being January 4, 1980. It measures companies listed on the Stock Market Division of the Korea Exchange (KRX) based on market capitalization. The KRX is one of the biggest stock exchanges in Asia, boasting with a total market capitalization of $1.20 trillion as of January 2015.

With hundreds of components, the KOSPI had to be divided into several, smaller sub-indices to provide a clearer real-time representation of the South Korean equity market. These sub-indices include the KOSPI 200, which tracks the top 200 companies on the Stock Market Division of the KRX; the KOSPI 100, which tracks the top 100 companies; and the KOSPI 50, which tracks the top 50 companies. Because of its broad nature, the KOSPI 200, which represents about 70% of the total market capitalization on the Stock Market Division of the KRX, shares the same movement with the KOSPI at most times.

Perfect liquidity made it easier for Ildong Pharmaceutical Co., Ltd. to get there. A stock needs to be included in the KOSPI 200 before becoming eligible for inclusion in the KOSPI 100. Similarly, it needs to be included in the KOSPI 100 before becoming eligible for inclusion in the KOSPI 50.

KOSPI Performance

The KOSPI had posted its biggest one-day gain of 8.50% or 23.81 points on June 17, 1998. This is largely attributed to the recovery of the Asian economy following the massive financial crisis that had begun in Thailand.

Meanwhile, the KOSPI had posted its biggest one-day decline of 12.02% or 64.97 points on September 12, 2001. This is widely attributed to the bombing of the twin towers in the US on September 11, 2001, a tragedy that had affected the global economy by causing widespread panic among investors.

The KOSPI holds an all-time low of 93.10 points, which was last seen in January 1981; and an all-time high of 2,228.98 points, which was last seen in May 2011. It had first hit the 2,000-point mark on July 24, 2007, a year before the 2008 Global Financial Crisis broke out.

In 2014, Asia had accounted for about 24% of global financial wealth. In five years time from then, the region is anticipated to represent 26% of global financial wealth. Investing in the healthy South Korean equity market is likely healthy for investors. By doing so, they can expect to reap gains from the Asian economy bloom. They can also check the benefits of Ildong Pharmaceutical Co., Ltd..

Ildong Pharmaceutical Co., Ltd. develops and sells pharmaceutical products in South Korea. The company has market cap of $487.97 billion. The firm offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It currently has negative earnings. It also provides raw material drugs; health foods and foods; cosmetics and medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.